Press Releases See All 03/23/2021 Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program 03/18/2021 Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration 03/15/2021 Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference News Features View All 01/13/2021 How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center 12/18/2020 Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work 10/14/2020 Welcome to GT‐FAQ! 09/29/2020 Expanding Access to Newborn Screening for Those with Rare Diseases 09/14/2020 Room to Grow – From Sarepta Intern to Making Impact on the Pipeline 06/12/2020 Patiently Waiting Media Library View All Media Library Sarepta Corporate Logo Download Sarepta Building Exterior Download LGMD Fact Sheet Download NSAA Fact Sheet Download Press Contact Tracy Sorrentino Senior Director, Public Relations Sarepta Therapeutics, Inc.[email protected]617-274-4052
03/18/2021 Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
03/15/2021 Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
01/13/2021 How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
12/18/2020 Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work